Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults.
Biogen Idec receives negative opinion from the CHMP on Fampyra
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.
Natalizumab Use During the Third Trimester of Pregnancy.
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
Gordon Research Conference on Immunochemistry & Immunobiology
Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo
Patient reported outcome measures in neurogenic bladder.
Current and future disease-modifying therapies in multiple sclerosis.
Spin-offs: Meet the structure specialists
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Symptom changes in multiple sclerosis following psychological interventions: a systematic review.
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Drug Safety Labeling Changes
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Pages